Open link in next tab
http://webcache.googleusercontent.com/search?q=cache%3Ahttps%3A%2F%2Fwww.economist.com%2Fbusiness%2F2023%2F10%2F08%2Fwho-profits-most-from-americas-baffling-health-care-system&sca_esv=572016509&strip=1&vwsrc=0
http://webcache.googleusercontent.com/search?q=cache%3Ahttps%3A%2F%2Fwww.economist.com%2Fbusiness%2F2023%2F10%2F08%2Fwho-profits-most-from-americas-baffling-health-care-system&sca_esv=572016509&strip=1&vwsrc=0
These events are symptoms of the deeper malaise in America’s dysfunctional health-care system. The country spends about $4.3trn a year on keeping citizens in good nick. That is equivalent to 17% of gdp, twice as much as the average in other rich economies. And yet American adults live shorter lives and American infants die more often than in similarly affluent places. Pharmaceutical firms and hospitals attract much of the public ire for the inflated costs. Much less attention is paid to a small number of middlemen who extract far bigger rents from the system’s complexity.
Over the past decade these firms have quietly increased their presence in America’s vast health-care industry. They do not make drugs and have not, until recently, treated patients. They are the intermediaries—insurers, pharmacies, drug distributors and pharmacy-benefit managers (pbms)—sitting between patients and their treatments. In 2022 the combined revenue of the nine biggest middlemen—call them big health—equated to around 45% of America’s health-care bill, up from 25% in 2013. Big health accounts for eight of the top 25 companies by revenue in the s&p 500 index of America’s leading stocks, compared with four for big tech and none for big pharma.